Global Posaconazole Market Expected To Register At 4.8% CAGR By 2021

Date: 2017-08-11

Posaconazole (trade name Noxafil, Posanol) is a triazole antifungal drug.

The growing number of immunocompromised patients and oropharyngeal candidiasis patients are the crucial factors propelling the Posaconazole market as it is used to treat invasive aspergillosis and candidiasis and fungal infections, and oropharyngeal candidiasis (OPC), according to research, the global Posaconazole market is expected to register at 4.8% CAGR by 2021.

Geographically, North America is expected to remain the largest market during the forecast period, The Asia Pacific is expected to grow at largest CAGR over the forecast period as where is the largest population and the largest geriatric population; the region followed by Europe, the Europe is to witness to register a CAGR of 3.1% during the forecast period.

Posaconazole is absorbed within three to five hours. It is predominately eliminated through the liver, and has a half-life of about 35 hours. Oral administration of posaconazole taken with a high-fat meal exceeds 90% bioavailability and increases the concentration by four times compared to fasting state

It is also used to treat invasive infections by Candida, Mucor, and Aspergillus species in severely immunocompromised patients. Clinical evidence for its utility in treatment of invasive disease caused by Fusarium species (fusariosis) is limited.

Global top manufacturers operating in Posaconazole market is Merck Noxafi.

Global Posaconazole market share by geography as following:

Read Full Report:

Joanna | Executive – International Business and partner Relations
E-mail: | Tel: 1-510-400-8520


Contact With Us
Join templatemonster at google+
Customized Research
Request Sample